| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 04/26/2011 | CA2430707C 8-{4-[3-(5-fluoro-1h-indol-3-yl)propyl]-piperazin-1-yl}-2-methyl-4h-benzo[1,4]oxazin-3-one mesylate with high affinity for the dopamine d2 receptor and the serotonin reuptake site |
| 04/26/2011 | CA2428785C Nanoparticulate compositions comprising a drug and copolymers of vinyl pyrrolidone and vinyl acetate as surface stabilizers |
| 04/26/2011 | CA2424565C Novel crystalline forms of a factor xa inhibitor |
| 04/26/2011 | CA2423628C Derivatives of tryptamine and analogous compounds, and pharmaceutical formulations containing them |
| 04/26/2011 | CA2420410C Pharmaceutical compositions for headache, migraine, nausea and emesis |
| 04/26/2011 | CA2414008C Gabapentin analogues for sleep disorders |
| 04/26/2011 | CA2408838C Drug/drug delivery systems for the prevention and treatment of vascular disease |
| 04/26/2011 | CA2402597C Composition for use in treatment of ocular hypertension and glaucoma |
| 04/26/2011 | CA2402099C Methods for the treatment of primary headache disorders using prostanoid ep4 receptor antagonists, and assays for agents for such treatment |
| 04/26/2011 | CA2400871C Novel malconic acid derivatives, processes for their preparation, their use as inhibitor of factor xa activity and pharmaceutical compositions containing them |
| 04/26/2011 | CA2388656C Use of biodegradable microspheres that release an anticancer agent for treating gliobastoma |
| 04/26/2011 | CA2371109C Improved pharmaceutical formulations |
| 04/26/2011 | CA2367508C Pesticidal enantiomer-pure 2,4-disubstituted oxazolines |
| 04/26/2011 | CA2364948C C16 unsaturated fp-selective prostaglandins analogs |
| 04/26/2011 | CA2359945C Inhibitors of crystallization in a solid dispersion |
| 04/26/2011 | CA2353554C Palladium-substituted bacteriochlorophyll derivatives and use thereof |
| 04/26/2011 | CA2345103C (r)-chiral halogenated 1-substitutedamino-(n+1)-alkanols useful for inhibiting cholesteryl ester transfer protein activity |
| 04/26/2011 | CA2337988C Inhibitors of proteasomal activity for stimulating bone and hair growth |
| 04/26/2011 | CA2309602C Methods and compositions for enhancing immune response and for the production of in vitro mabs |
| 04/26/2011 | CA2306024C Buccal, polar and non-polar spray or capsule |
| 04/26/2011 | CA2264012C Compositions and methods for polynucleotide delivery |
| 04/26/2011 | CA2215394C Il-17 receptor |
| 04/26/2011 | CA2201482C Novel ectoparasite saliva proteins and apparatus to collect such proteins |
| 04/22/2011 | CA2684017A1 Ectonucleotidase pyrophosphate/phosphodiesterase-1 (enpp-1) as a target for the treatment of aortic valve stenosis and cardiovascular calcification |
| 04/21/2011 | WO2011047390A2 Heterocyclic benzoxazole compositions as inhibitors of hepatitis c virus |
| 04/21/2011 | WO2011047384A2 Methods of inhibiting ire1 |
| 04/21/2011 | WO2011047374A1 Methods of treating tauopathies |
| 04/21/2011 | WO2011047350A2 Emesis treatment |
| 04/21/2011 | WO2011047341A2 Treatment of suicidal ideation or behavior using inhibitors of nicotinic acetylcholine receptors |
| 04/21/2011 | WO2011047323A2 Antimicrobial compounds and methods of making and using the same |
| 04/21/2011 | WO2011047320A2 Antimicrobial compounds and methods of making and using the same |
| 04/21/2011 | WO2011047319A2 Antimicrobial compounds and methods of making and using the same |
| 04/21/2011 | WO2011047315A1 Subsitituted benzimidazoles |
| 04/21/2011 | WO2011047312A1 Hbv antisense inhibitors |
| 04/21/2011 | WO2011047309A2 Treatment of ischemic tissue |
| 04/21/2011 | WO2011047259A1 Compositions |
| 04/21/2011 | WO2011047238A1 Combination |
| 04/21/2011 | WO2011047195A1 Treating neurotoxicity associated with combinations of 5 - fu or its prodrugs and dpd inhibitors |
| 04/21/2011 | WO2011047178A1 Colon cleansing of residual stool and secretions during colonoscopy |
| 04/21/2011 | WO2011047173A2 Pharmaceutical compositions for oral administration |
| 04/21/2011 | WO2011047165A1 Methods for treating memory impairment |
| 04/21/2011 | WO2011047156A1 Sepiapterin reductase inhibitors for the treatment of pain |
| 04/21/2011 | WO2011047143A1 Compositions and methods for mild sedation, anxiolysis and analgesia in the procedural setting |
| 04/21/2011 | WO2011047129A1 Treatment of neurodegenerative diseases, causation of memory enhancement, and assay for screening compounds for such |
| 04/21/2011 | WO2011047119A1 Compounds for the treatment of hepatitis c |
| 04/21/2011 | WO2011047048A1 Combination therapy treatment for viral infections |
| 04/21/2011 | WO2011046997A1 Cgrp receptor antagonists |
| 04/21/2011 | WO2011046991A2 Certain substituted ureas as modulators of kinase activity |
| 04/21/2011 | WO2011046978A2 Steroidal compounds as melanogenesis modifiers and uses thereof |
| 04/21/2011 | WO2011046970A1 Amino - pyrimidine compounds as inhibitors of tbkl and/or ikk epsilon |
| 04/21/2011 | WO2011046964A2 Inhibitors of bruton's tyrosine kinase |
| 04/21/2011 | WO2011046954A1 Hematopoietic growth factor mimetic small molecule compounds and their uses |
| 04/21/2011 | WO2011046946A2 Bifunctional molecules with antibody-recruiting and entry inhibitory activity against the human immunodeficiency virus |
| 04/21/2011 | WO2011046916A1 N-((1r,2s,5r)-5-(tert-butylamino)-2-((s)-3-(7-tert-butylpyrazolo[1,5-a][1,3,5]triazin-4-ylamino)-2-oxopyrrolidin-1-yl)cyclohexyl)acetamide, a dual modulator of chemokine receptor activity, crystalline forms and processes |
| 04/21/2011 | WO2011046905A2 Pharmaceutical compositions |
| 04/21/2011 | WO2011046901A2 Broad spectrum antiviral and methods of use |
| 04/21/2011 | WO2011046894A1 Combination |
| 04/21/2011 | WO2011046873A1 Hiv integrase inhibitors |
| 04/21/2011 | WO2011046851A1 Spiropiperidine compounds and pharmaceutical use thereof for treating diabetes |
| 04/21/2011 | WO2011046811A1 Combinations of a specific hcv ns5a inhibitor and an hcv ns3 protease inhibitor |
| 04/21/2011 | WO2011046800A1 3-substituted compounds for reducing uric acid |
| 04/21/2011 | WO2011046774A1 Diaryl ether derivatives as notch sparing gamma secretase inhibitors |
| 04/21/2011 | WO2011046771A1 SUBSTITUTED PIPERIDINES THAT INCREASE p53 ACTIVITY AND THE USES THEREOF |
| 04/21/2011 | WO2011046757A2 Accelerating thrombus resolution through augmentation of p53 activity |
| 04/21/2011 | WO2011046733A1 Polymorphs of bromfenac sodium and methods for preparing bromfenac sodium polymorphs |
| 04/21/2011 | WO2011046646A2 Inhibitors of filovirus entry into host cells |
| 04/21/2011 | WO2011046634A1 Infectious clones of torque teno virus |
| 04/21/2011 | WO2011046599A2 Treatment and prognosis with thalidomide in multiple myeloma based on karyotyping and gene expression profiling |
| 04/21/2011 | WO2011046596A2 Anti-cancer tamoxifen-melatonin hybrid ligand |
| 04/21/2011 | WO2011046569A1 Process for the preparation of f-series prostaglandins |
| 04/21/2011 | WO2011046546A1 Delayed release compositions |
| 04/21/2011 | WO2011046515A1 Antiproliferative agent |
| 04/21/2011 | WO2011046470A1 Therapeutic medium for preventing and treating adenomas and prostatitis |
| 04/21/2011 | WO2011046457A1 Anti-neoplastic uses of artemin antagonists |
| 04/21/2011 | WO2011046451A1 Maintaining or increasing cognitive development |
| 04/21/2011 | WO2011046423A1 High-purity rebaudioside d and applications |
| 04/21/2011 | WO2011046411A2 Chestnut extracts with neuro cellular protective activity and acetylcholinesterase inhibiting activity, and use thereof |
| 04/21/2011 | WO2011046382A2 Nrf2 inhibitors and use thereof |
| 04/21/2011 | WO2011046381A2 COMPOSITION FOR INHIBITING TGF-β COMPRISING IMIDAZOPURINE DERIVATIVES |
| 04/21/2011 | WO2011046303A2 Novel method for preparing entecavir and intermediate used therein |
| 04/21/2011 | WO2011046267A1 Silver/polydiguanide complex, preparation method thereof, and antibacterial composition containing the same as an active ingredient |
| 04/21/2011 | WO2011046239A1 Novel usage of imidazole compound |
| 04/21/2011 | WO2011046221A1 INTERFERON-α MODULATOR |
| 04/21/2011 | WO2011046204A1 Marker associated with non-alcoholic steatohepatitis |
| 04/21/2011 | WO2011046200A1 Antiinflammatory agent comprising differentiation-inducing factor or analog thereof |
| 04/21/2011 | WO2011046199A1 Method for producing reduced coenzyme q10, method for stabilizing same, and composition comprising same |
| 04/21/2011 | WO2011046193A1 Aptamer capable of binding to viral hemorrhagic septicemia virus |
| 04/21/2011 | WO2011046158A1 Rhodacyanine derivative and pharmaceutical composition for treating leishmaniasis |
| 04/21/2011 | WO2011046057A1 Novel sugar chain compound containing sialyllactosamine-type or sialyl lewis x-type sialic acid and fucose |
| 04/21/2011 | WO2011045934A1 Method for producing reduced coenzyme q10, method for stabilizing same, and composition comprising same |
| 04/21/2011 | WO2011045811A1 Fused thiazolo and oxazolo pyrimidinones |
| 04/21/2011 | WO2011045810A1 Pharmaceutical compositions containing taurine and race-methionine for the treatment of alcoholism |
| 04/21/2011 | WO2011045809A1 Liposomal amphotericin formulation comprising cholesterol for treating fungal infections |
| 04/21/2011 | WO2011045796A1 Compositions for controlling varroa mites in bees |
| 04/21/2011 | WO2011045775A1 A delayed release pharmaceutical composition of mesalamine |
| 04/21/2011 | WO2011045769A2 Anti-misuse solid oral dosage form provided having a modified specific release profile |
| 04/21/2011 | WO2011045702A1 Pyrrolo[2,3-d] pyrimidine compounds |
| 04/21/2011 | WO2011045646A1 Imidazothiazole-chalcone derivatives as potential anticancer agents and process for the preparation thereof |
| 04/21/2011 | WO2011045594A1 Novel macrocycles and methods for their production |
| 04/21/2011 | WO2011045593A1 Novel macrocyles and methods for their production |